Stille completes the acquisition of Fehling Instruments
Stille AB (publ) has successfully completed the previously announced acquisition of the German instrument provider Fehling (Fehling Instruments GmbH & Co. KG, Fehling Verwaltungs GmbH, and associated subsidiaries, collectively referred to as "Fehling"). All conditions for the transaction and acquisition have now been met. As previously communicated, Stille has paid 36 million euros in cash upon the completion of the acquisition on a debt-free and cash-free basis. The acquisition is financed through the previously announced targeted issuance of SEK 425 million.
Fehling develops and sells high-quality medical instruments, focusing on demanding specialties such as open and minimally invasive cardiac, thoracic, neuro, and spine surgery. Fehling has a global sales presence through a combination of direct sales and distributors. Through the acquisition, Stille significantly expands its product range, research and development capacity, and global presence.
Torshälla, January 25th, 2024.